Promising Pipeline and FDA Fast Track Designations Justify Buy Rating for Adicet Bio

Adicet Bio (ACET) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns.

Robert Burns’s rating is based on the promising potential of Adicet Bio’s pipeline, particularly the ADI-270 candidate, which is being developed as a treatment for CD70+ cancers. This candidate has shown significant promise in preclinical trials, demonstrating enhanced tumor control and cytotoxicity, especially in CD70-low tumors, compared to other CAR T cell therapies. The FDA’s Fast Track Designation for ADI-270 in treating metastatic clear cell renal cell carcinoma further underscores its potential efficacy and accelerates its development timeline.
Additionally, Adicet Bio’s ADI-001 candidate, targeting autoimmune diseases, has also received FDA Fast Track Designation for several conditions, including systemic lupus erythematosus and systemic sclerosis. Although the competitive landscape in autoimmune therapies is noted, the initial positive results from ADI-001 in other trials suggest potential success in these new indications. These factors contribute to a partially risk-mitigated outlook, justifying the Buy rating and a 12-month price target of $4.